# BB Biotech

> BB Biotech is a VC fund backing Biotechnology and Pharmaceutical. See 4 investments, round sizes, portfolio and contact details. Updated Oct 2026.

- Type: VC Fund
- Location: Schaffhausen, Switzerland
- Total investments: 4
- Last investment: Oct 2026
- Lead investor: 0%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/company/bb-biotech/
- X (Twitter): https://x.com/bb_biotech_ag
- Website: http://www.bbbiotech.ch/

BB Biotech is an equity fund launched and managed by Bellevue Asset Management. It invests in the public equity markets across the globe. BB Biotech primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. It employs a fundamental analysis to create its portfolio. BB Biotech began operation on November 09, 1993. It has its headquarters in Schaffhausen in Switzerland.

## Contacts

5 contacts available for BB Biotech. Shizune tracks 5 team members at BB Biotech. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bb-biotech-ag?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 100% |
| Pharmaceutical | 3 | 75% |
| Medical | 2 | 50% |
| Therapeutics | 2 | 50% |
| Biopharma | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Private Equity | 2 | 50% |
| Series B | 1 | 25% |
| Post-IPO Equity | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christian Koch | Portfolio Manager | 0 | — |
| Clive Meanwell | Vice Chairman | 4 | https://shizune.co/investors/profile/clive-meanwell |
| Michael Hutter | Chief Financial Officer | 0 | — |
| Stephen Taubenfeld | Portfolio Manager | 0 | — |
| Tanja Chicherio | Head of Marketing and Communications | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Matchpoint Therapeutics | Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning, and covalent chemistry libraryevolution. Matchpoint has an emerging pipeline of novel covalent medicines, initially focused on immunology. | $150M | Series B | Oct 07, 2026 | https://matchpointtx.com/ |
| Avere Therapeutics | Avere Therapeutics is a biotechnology company that develops oral interleukin-23 receptor antagonist therapies for chronic inflammatory diseases. The company is advancing AVR-001, an oral, once-weekly IL-23 receptor antagonist designed to modulate IL-23 signaling. Its work focuses on leveraging a validated immunology target with clinical proof ofconcept across conditions such as psoriasis, ulcerative colitis, Crohn’s disease, and psoriatic arthritis. Avere Therapeutics concentrates on achieving convenient dosing while maintaining efficacy through higher and more consistent drug exposure and a longer half-life. Its programs are intended to offer pill-based treatment options for patients who currently rely on injectable IL-23 inhibitors. | $500M | Private Equity | Aug 10, 2026 | https://www.averetx.com |
| LB Pharmaceuticals | LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $150M | Post-IPO Equity | Jul 29, 2026 | http://lbpharma.us/ |
| Mentari Therapeutics | Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M | Private Equity | Jul 22, 2026 | https://mentaritx.com |

4 of 4 investments shown.

## Co-investors
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 3 deals together
- [ADAR1 Capital Management](https://shizune.co/investors/profile/adar1-capital-management) — VC Fund, 2 deals together
- Blackstone Multi-Asset Investing — VC Fund, 2 deals together
- [Commodore Capital](https://shizune.co/investors/profile/commodore-capital) — VC Fund, 2 deals together
- [Deep Track Capital](https://shizune.co/investors/profile/deep-track-capital) — VC Fund, 2 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund
- [Foresight Group](https://shizune.co/investors/profile/foresight-group) — VC Fund

## FAQ

### What does BB Biotech invest in?

BB Biotech invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Private Equity and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BB Biotech?

Public channels for BB Biotech include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BB Biotech?

The team at BB Biotech includes Christian Koch (Portfolio Manager), Clive Meanwell (Vice Chairman) and Michael Hutter (Chief Financial Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co